Binah Capital Group, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Binah Capital Group, Inc. Binah Capital Group, Inc. (NASDAQ:BCG) operates as a financial services holding company that owns and manages a network of independent broker-dealers and wealth management firms, providing independent financial advisors with execution, compliance, technology, and back-office support services. The company offers access to stock, bond, exchange-traded fund, and options execution services; research, compliance, supervision, accounting, and related support for advisors; mutual funds and insurance products including fixed and variable annuities; and alternative investments such as non-traded real estate investment trusts and unit trusts; advisory fees; securities commissions; and commissions from variable annuities and other insurance products. Binah Capital Group, Inc. focuses on consolidating fragmented independent broker-dealers to achieve economies of scale in a technology-driven regulatory environment, serving financial advisors and their clients primarily in the United States through subsidiaries including Wentworth Management Services LLC, Purshe Kaplan Sterling Investments, Inc., and Cabot Lodge Securities, LLC; founded in 2016, the company maintains headquarters at 80 State Street in Albany, New York, and employs approximately 150 people under CEO Craig Gould. In recent developments, Binah Capital Group, Inc. plays a key role in major industry consolidations, earning recognition in Financial Planning's "Top IBD Moves and M&A Deals of 2024" list for involvement in four significant transactions featuring affiliates with Americana Partners, Merit Financial Advisors, Wentworth Management Services, and Perigon Wealth Management, underscoring its strategy to facilitate partnerships, scale operations, and expand market presence amid sector consolidation. The company reports revenue growth, with total revenues reaching $90.4 million for the six months ended June 30, 2025, up from prior periods, alongside assets under management increases and ongoing issuances of Series A redeemable convertible preferred stock and Series B convertible preferred stock to support expansion.
Company News
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
Binah Capital Group, Inc. (NASDAQ:BCG) Stock Short Interest Report for September
Head-To-Head Comparison: Binah Capital Group (NASDAQ:BCG) versus Hennessy Advisors (NASDAQ:HNNA)
Binah Capital Group (NASDAQ:BCG) and PennantPark Investment (NASDAQ:PNNT) Financial Survey
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
New ABB and BCG Report Highlights Growing Role of Direct Current Technologies in Future Power Systems
New ABB and BCG report highlights growing role of direct current technologies in future power systems
Binah Capital Group Reports Results for Second Quarter of 2026
Binah Capital Group to Participate in Sidoti Micro-Cap Virtual Conference August 19-20
BCG CEO: AI adoption now as high on CEOs' agenda as profits
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
81% of Enterprises Report AI Initiatives Delayed, Scaled Back, or Abandoned Due to Data Permission and Governance Gaps, Finds Transcend Research
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
TVS Motor Company Ranked #1 Globally For Shareholder Value Creation In 'Durable Consumer Goods' By WirtschaftsWoche And Boston Consulting Group
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States